Current Report Filing (8-k)
November 27 2020 - 4:36PM
Edgar (US Regulatory)
0001410098
false
0001410098
2020-11-27
2020-11-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): November 27, 2020
CORMEDIX INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-34673
|
|
20-5894890
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
300 Connell Drive, Suite 4200
Berkeley Heights, NJ
|
|
07922
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (908) 517-9500
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2, below):
|
☐
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Exchange
Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common stock, $0.001 par value
|
|
CRMD
|
|
NYSE American LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On November 27, 2020, CorMedix Inc. (the “Company”),
entered into an Amended and Restated At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities,
Inc. (formerly known as B. Riley FBR, Inc.)(“B. Riley Securities”) and Needham & Company, LLC (“Needham & Company”) as sales agents, pursuant to which the Company may sell, from time to time, an aggregate of up to $25,000,000
of its common stock, par value $0.001 per share (the “Shares”).
The Shares may be issued and sold from time to time through or to
B. Riley Securities and Needham & Company acting as sales agent or principal pursuant to the Company’s shelf Registration
Statement on Form S-3 (Reg. No. 333-249901). The Company will file a prospectus supplement, effective November 27, 2020, pursuant
to Rule 424(b) under the Securities Act of 1933, as amended, with respect to the Shares. Sales of the Shares, if any, under such
prospectus supplement may be made in transactions that are deemed to be “at the market offerings” pursuant to Rule
415 under the Securities Act of 1933, as amended.
The Company will pay the applicable sales agents a commission equal
to 3% of the gross sales price per share for any Shares sold through such sales agents under the Sales Agreement. The Company has
provided the sales agents with customary indemnification and contribution rights.
The foregoing description is qualified in its entirety by reference
to the Sales Agreement, a copy of which is included as Exhibit 1.1 hereto and is incorporated by reference herein.
|
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CORMEDIX INC.
|
|
|
|
Date: November 27, 2020
|
By:
|
/s/ Khoso Baluch
|
|
Name:
|
Khoso Baluch
|
|
Title:
|
Chief Executive Officer
|
2
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Apr 2023 to Apr 2024